These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 24910102)

  • 1. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression.
    Lai R; Katalinic N; Glue P; Somogyi AA; Mitchell PB; Leyden J; Harper S; Loo CK
    World J Biol Psychiatry; 2014 Sep; 15(7):579-84. PubMed ID: 24910102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
    Wan LB; Levitch CF; Perez AM; Brallier JW; Iosifescu DV; Chang LC; Foulkes A; Mathew SJ; Charney DS; Murrough JW
    J Clin Psychiatry; 2015 Mar; 76(3):247-52. PubMed ID: 25271445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
    Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
    Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
    George D; Gálvez V; Martin D; Kumar D; Leyden J; Hadzi-Pavlovic D; Harper S; Brodaty H; Glue P; Taylor R; Mitchell PB; Loo CK
    Am J Geriatr Psychiatry; 2017 Nov; 25(11):1199-1209. PubMed ID: 28739263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
    Feder A; Parides MK; Murrough JW; Perez AM; Morgan JE; Saxena S; Kirkwood K; Aan Het Rot M; Lapidus KA; Wan LB; Iosifescu D; Charney DS
    JAMA Psychiatry; 2014 Jun; 71(6):681-8. PubMed ID: 24740528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
    Lenze EJ; Farber NB; Kharasch E; Schweiger J; Yingling M; Olney J; Newcomer JW
    World J Biol Psychiatry; 2016 Apr; 17(3):230-8. PubMed ID: 26919405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
    Loo CK; Gálvez V; O'Keefe E; Mitchell PB; Hadzi-Pavlovic D; Leyden J; Harper S; Somogyi AA; Lai R; Weickert CS; Glue P
    Acta Psychiatr Scand; 2016 Jul; 134(1):48-56. PubMed ID: 27028832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
    Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
    Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disentangling the association of depression on the anti-fatigue effects of ketamine.
    Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
    J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
    Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
    Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
    Singh JB; Fedgchin M; Daly EJ; De Boer P; Cooper K; Lim P; Pinter C; Murrough JW; Sanacora G; Shelton RC; Kurian B; Winokur A; Fava M; Manji H; Drevets WC; Van Nueten L
    Am J Psychiatry; 2016 Aug; 173(8):816-26. PubMed ID: 27056608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
    Mathew SJ; Murrough JW; aan het Rot M; Collins KA; Reich DL; Charney DS
    Int J Neuropsychopharmacol; 2010 Feb; 13(1):71-82. PubMed ID: 19288975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
    aan het Rot M; Collins KA; Murrough JW; Perez AM; Reich DL; Charney DS; Mathew SJ
    Biol Psychiatry; 2010 Jan; 67(2):139-45. PubMed ID: 19897179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
    Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W
    Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.
    Pattanaseri K; Lortrakul J; Jaisin K; Srifuengfung M; Sa-Nguanpanich N; Viravan N; Pariwatcharakul P; Makarasara W; Ratta-Apha W
    BMC Psychiatry; 2024 Jul; 24(1):512. PubMed ID: 39026266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.